Practical Approach to Abnormal Liver Enzymes in Patients with Inflammatory Bowel Disease

Authors

  • Davide De Marco, MDCM Division of Gastroenterology and Hepatology, McGill University, Montreal, QC
  • Amine Benmassaoud, MDCM, MSc, FRCPC Division of Gastroenterology and Hepatology, McGill University, Montreal, QC

DOI:

https://doi.org/10.58931/cibdt.2023.1317

Abstract

Inflammatory Bowel Diseases (IBD) are chronic inflammatory conditions that can impact organ systems beyond the gastrointestinal tract. Extraintestinal manifestations (EIMs) of IBDs are common and can occur at any stage of the disease. While EIMS most commonly involve the musculoskeletal system, up to 35% of individuals with IBD exhibit hepatobiliary involvement at some point during the course of their disease, often independently of disease activity. Chronic hepatobiliary diseases are noted in 5% of patients with IBD. These diseases manifest with indicative symptoms, abnormal liver biochemistry tests, or radiological abnormalities. This review provides a comprehensive outline and approach to abnormal liver enzymes in individuals with IBD.

Author Biographies

Davide De Marco, MDCM, Division of Gastroenterology and Hepatology, McGill University, Montreal, QC

Dr. Davide De Marco is a fourth-year gastroenterology and hepatology resident at McGill University. He completed his medical school training at McGill University in 2020 and his Internal Medicine residency at McGill University in 2023. He has a wide range of clinical interests in gastroenterology including inflammatory bowel diseases and hepatology.

Amine Benmassaoud, MDCM, MSc, FRCPC, Division of Gastroenterology and Hepatology, McGill University, Montreal, QC

Dr. Amine Benmassaoud completed his medical training and specialty training in Gastroenterology at McGill University. He then pursued an advanced fellowship in hepatology at the Sheila Sherlock Liver Centre, Royal Free Hospital, London England thanks to the support of the Canadian Association for the Study of the Liver Clinical Fellowship award. He recently completed his Master’s in Experimental Medicine at McGill University. He is currently an assistant professor of medicine, and member of the Division of Gastroenterology and Hepatology at McGill University Health Centre in Montreal. As an early career clinician-investigator, his special interest is the evaluation and management of portal hypertension.

References

Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118-32. doi: 10.1053/j.gastro.2021.07.042 DOI: https://doi.org/10.1053/j.gastro.2021.07.042

Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982-92. doi: 10.1097/MIB.0000000000000392 DOI: https://doi.org/10.1097/MIB.0000000000000392

Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102(2):344-50. doi: 10.1111/j.1572-0241.2006.00947.x DOI: https://doi.org/10.1111/j.1572-0241.2006.00947.x

Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: a review for clinicians. World J Hepatol. 2021;13(11):1688-98. doi: 10.4254/wjh.v13.i11.1688 DOI: https://doi.org/10.4254/wjh.v13.i11.1688

Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenerol. 2017;112(1):18-35. doi: 10.1038/ajg.2016.517. DOI: https://doi.org/10.1038/ajg.2016.517

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update. J Hepatol. 2021;75(3):659-89. doi: 10.1016/j.jhep.2021.05.025 DOI: https://doi.org/10.1016/j.jhep.2021.05.025

Cheng YW, McLean R, Sewell JL, Huang CY, Khalili M. Inflammatory bowel disease type influences development of elevated liver enzymes. JGH Open. 2022;6(12):846-53. doi: 10.1002/jgh3.12831 DOI: https://doi.org/10.1002/jgh3.12831

Cappello M, Randazzo C, Bravatà I, Licata A, Peralta S, Craxì A, et al. Liver function test abnormalities in patients with inflammatory bowel diseases: a hospital-based survey. Clin Med Insights Gastroenterol. 2014;7:25-31. doi: 10.4137/CGast.S13125. DOI: https://doi.org/10.4137/CGast.S13125

Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2020;27(6):947-55. doi: 10.1093/ibd/izaa189 DOI: https://doi.org/10.1093/ibd/izaa189

Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1937-44. doi: 10.1097/MIB.0000000000000832 DOI: https://doi.org/10.1097/MIB.0000000000000832

Mancina RM, Spagnuolo R, Milano M, Brogneri S, Morrone A, Cosco C, et al. PNPLA3 148M carriers with inflammatory bowel diseases have higher susceptibility to hepatic steatosis and higher liver enzymes. Inflamm Bowel Dis. 2016;22(1):134-40. doi: 10.1097/MIB.0000000000000569 DOI: https://doi.org/10.1097/MIB.0000000000000569

Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6-19. doi: 10.1136/gutjnl-2017-314924 DOI: https://doi.org/10.1136/gutjnl-2017-314924

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-835. doi: 10.1097/HEP.0000000000000323 DOI: https://doi.org/10.1097/HEP.0000000000000323

Saroli Palumbo C, Restellini S, Chao C-Y, Aruljothy A, Lemieux C, Wild G, et al. Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography. Inflamm Bowel Dis. 2018;25(1):124-33. doi: 10.1093/ibd/izy200 DOI: https://doi.org/10.1093/ibd/izy200

Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology. 2021;161(6):1865-77. doi: 10.1053/j.gastro.2021.08.032 DOI: https://doi.org/10.1053/j.gastro.2021.08.032

Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology. 2016;151(4):660-9. e4. doi: 10.1053/j.gastro.2016.06.021 DOI: https://doi.org/10.1053/j.gastro.2016.06.021

Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14(3):331-7. doi: 10.3748/wjg.14.331 DOI: https://doi.org/10.3748/wjg.14.331

Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659-702. doi: 10.1002/hep.32771 DOI: https://doi.org/10.1002/hep.32771

Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48-54. doi: 10.1067/mge.2002.125367 DOI: https://doi.org/10.1067/mge.2002.125367

Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, Muri Boberg K, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology. 2011;53(6):1977-85. doi: 10.1002/hep.24307 DOI: https://doi.org/10.1002/hep.24307

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761-806. doi: 10.1016/j.jhep.2022.05.011 DOI: https://doi.org/10.1016/j.jhep.2022.05.011

DeFilippis EM, Kumar S. Clinical presentation and outcomes of autoimmune hepatitis in inflammatory bowel disease. Dig Dis Sci. 2015;60(10):2873-80. doi: 10.1007/s10620-015-3699-4. DOI: https://doi.org/10.1007/s10620-015-3699-4

Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671-722. doi: 10.1002/hep.31065 DOI: https://doi.org/10.1002/hep.31065

Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169-76. doi: 10.1002/hep.22322. DOI: https://doi.org/10.1002/hep.22322

Colina F, Molero A, Casís B, Martínez-Montiel P. Infliximab-related hepatitis: a case study and literature review. Dig Dis Sci. 2013;58:3362-7. doi: 10.1007/s10620-013-2698-6. DOI: https://doi.org/10.1007/s10620-013-2698-6

Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657-63. doi: 10.1016/S0140-6736(09)61963-2 DOI: https://doi.org/10.1016/S0140-6736(09)61963-2

Gizard E, Ford AC, Bronowicki J-P, Peyrin-Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40(1):3-15. doi: 10.1111/apt.12794 DOI: https://doi.org/10.1111/apt.12794

Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Naymagon S, Mascarenhas J, et al. The natural history, treatments, and outcomes of portal vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(2):215-23. doi: 10.1093/ibd/izaa053 DOI: https://doi.org/10.1093/ibd/izaa053

Benmassaoud A, AlRubaiy L, Yu D, Chowdary P, Sekhar M, Parikh P, et al. A stepwise thrombolysis regimen in the management of acute portal vein thrombosis in patients with evidence of intestinal ischaemia. Aliment Pharmacol Ther. 2019;50(9):1049-58. doi: 10.1111/apt.15479 DOI: https://doi.org/10.1111/apt.15479

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64(1):179-202. DOI: https://doi.org/10.1016/j.jhep.2015.07.040

Baig MM, Irfan SA, Sumbal A, Sumbal R, Kumar S, Ahmad J, et al. Prevalence of gallstones in ulcerative colitis and crohn’s disease: a systematic review and meta-analysis. Cureus. 2022;14(6):e26121. doi: 10.7759/cureus.26121 DOI: https://doi.org/10.7759/cureus.26121

Restellini S, Chazouillères O, Frossard J-L. Hepatic manifestations of inflammatory bowel diseases. Liver Int. 2017;37(4):475-89. doi: 10.1111/liv.13265 DOI: https://doi.org/10.1111/liv.13265

Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta‐analysis. J Dig Dis. 2015 Nov;16(11):634-41. doi: 10.1111/1751-2980 DOI: https://doi.org/10.1111/1751-2980.12286

Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, et al. Management of hepatitis B virus infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. Can Liver J. 2018;1(4):156-217. doi: 10.3138/canlivj.2018-0008 DOI: https://doi.org/10.3138/canlivj.2018-0008

Núñez F P, Quera R, Bay C, Castro F, Mezzano G. Drug-induced liver injury used in the treatment of inflammatory bowel disease. J Crohns Colitis. 2022;16(7):1168-76. doi: 10.1093/ecco-jcc/jjac013 DOI: https://doi.org/10.1093/ecco-jcc/jjac013

Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44. e3. doi: 10.1053/j.gastro.2014.10.038. DOI: https://doi.org/10.1053/j.gastro.2014.10.038

Rahier J-F, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3(2):47-91. doi: 10.1016/j.crohns.2009.02.010 DOI: https://doi.org/10.1016/j.crohns.2009.02.010

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222-61. doi: 10.1016/j.jhep.2019.02.014 DOI: https://doi.org/10.1016/j.jhep.2019.02.014

Hoofnagle JH. LiverTox: a website on drug-induced liver injury. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease 3rd ed. Elsevier; 2013. p. 725-32. DOI: https://doi.org/10.1016/B978-0-12-387817-5.00040-6

Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14. doi: 10.3390/ijms17010014 DOI: https://doi.org/10.3390/ijms17010014

Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19(7):1404-10. doi: 10.1097/MIB.0b013e318281f28f. DOI: https://doi.org/10.1097/MIB.0b013e318281f28f

Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: recent topics and their role in the treatment of inflammatory bowel diseases. Front Pharmacol. 2021;11:582291. doi: 10.3389/fphar.2020.582291 DOI: https://doi.org/10.3389/fphar.2020.582291

Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007;102(7):1518-27. doi: 10.1111/j.1572-0241.2007.01187.x DOI: https://doi.org/10.1111/j.1572-0241.2007.01187.x

Benmassaoud A, Xie X, AlYafi M, Theoret Y, Bitton A, Afif W, et al. Thiopurines in the management of Crohn's disease: safety and efficacy profile in patients with normal TPMT activity-a retrospective study. Can J Gastroenterol Hepatol. 2016;2016:1034834. doi: 10.1155/2016/1034834 DOI: https://doi.org/10.1155/2016/1034834

Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. Inflamm bowel dis. 2013;19(9):2031-40. doi: 10.1097/MIB.0b013e3182920108 DOI: https://doi.org/10.1097/MIB.0b013e3182920108

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. J Crohns Colitis. 2020;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180 DOI: https://doi.org/10.1093/ecco-jcc/jjz180

Saibeni S, Bollani S, Losco A, Michielan A, Sostegni R, Devani M, et al. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012;44(2):123-7. doi: 10.1016/j.dld.2011.09.015 DOI: https://doi.org/10.1016/j.dld.2011.09.015

De Marco D, Bessissow T, Marcus V, Benmassaoud A. Vedolizumab-associated hypereosinophilia and hepatoxicity. ACG Case Rep J. 2022;9(11):e00905. doi: 10.14309/crj.0000000000000905 DOI: https://doi.org/10.14309/crj.0000000000000905

D’Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631. doi: 10.1177/1756284819848631 DOI: https://doi.org/10.1177/1756284819848631

Downloads

Published

2023-10-30

How to Cite

1.
De Marco D, Benmassaoud A. Practical Approach to Abnormal Liver Enzymes in Patients with Inflammatory Bowel Disease. Can IBD Today [Internet]. 2023 Oct. 30 [cited 2024 Nov. 19];1(3):14–20. Available from: https://canadianibdtoday.com/article/view/1-3-de_marco_benmassaoud

Issue

Volume 1, Issue 3, October 2023

Section

Articles

License

Copyright (c) 2023 Canadian IBD Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.